Terumo Corp. (OTCMKTS:TRUMY – Get Free Report)’s share price gapped up prior to trading on Friday. The stock had previously closed at $13.2545, but opened at $14.53. Terumo shares last traded at $14.3720, with a volume of 761,457 shares.
Analyst Upgrades and Downgrades
Separately, Nomura upgraded Terumo from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy”.
Check Out Our Latest Analysis on TRUMY
Terumo Price Performance
Terumo (OTCMKTS:TRUMY – Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.13. The business had revenue of $1.97 billion during the quarter, compared to analyst estimates of $1.84 billion. Terumo had a net margin of 13.83% and a return on equity of 10.44%. Equities research analysts anticipate that Terumo Corp. will post 0.86 earnings per share for the current year.
About Terumo
Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells products used in hospitals, clinics and other healthcare settings. Founded in 1921 by a group of Japanese medical doctors, the company initially produced clinical thermometers and has since expanded into a global provider of medical devices and related services.
Terumo’s principal businesses include cardiac and vascular products, blood and cell technologies, and general hospital solutions.
Further Reading
- Five stocks we like better than Terumo
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
- Microsoft Is Almost Back to $555—Now the Hard Part Begins
- Marvell Says Connecting AI Chips Could Be a $37 Billion Business—These 2 Stocks Rallied Too
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
